NARI Stock Overview Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. More details
Rewards Risk Analysis No risks detected for NARI from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Inari Medical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Inari Medical Historical stock prices Current Share Price US$55.45 52 Week High US$66.61 52 Week Low US$36.73 Beta 0.97 1 Month Change 11.66% 3 Month Change 28.45% 1 Year Change -15.61% 3 Year Change -38.04% 5 Year Change n/a Change since IPO 30.44%
Recent News & Updates
Inari Medical, Inc. Announces Reimbursement Approval for ClotTriever Thrombectomy System in Japan Dec 03
Director notifies of intention to sell stock Nov 19
Inari Medical, Inc. (NASDAQ:NARI) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable Nov 07
CEO, President & Director notifies of intention to sell stock Nov 01
Inari Medical, Inc. Announces Positive Results from the Prospective Peerless Randomized Controlled Trial Comparing Flowtriever to Catheter-Directed Thrombolytics Oct 30
New minor risk - Shareholder dilution Oct 29 See more updates
Inari Medical, Inc. Announces Reimbursement Approval for ClotTriever Thrombectomy System in Japan Dec 03
Director notifies of intention to sell stock Nov 19
Inari Medical, Inc. (NASDAQ:NARI) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable Nov 07
CEO, President & Director notifies of intention to sell stock Nov 01
Inari Medical, Inc. Announces Positive Results from the Prospective Peerless Randomized Controlled Trial Comparing Flowtriever to Catheter-Directed Thrombolytics Oct 30
New minor risk - Shareholder dilution Oct 29
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 29 Inari Medical, Inc. Provides Earnings Guidance for First Half of 2025
Inari Medical, Inc. to Report Q3, 2024 Results on Oct 28, 2024 Oct 08
Investors Interested In Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Sep 23
Chief Financial Officer notifies of intention to sell stock Sep 15
Inari Medical, Inc. Announces Peerless Data to Be Presented During the Late-Breaking Clinical Trial Sessions At Tct2024 Aug 30
Director notifies of intention to sell stock Aug 21
Consensus EPS estimates fall by 21% Aug 06 Inari Medical, Inc. Announces CFO Changes
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 01
Now 22% undervalued Jul 28
Chief Medical Officer notifies of intention to sell stock Jul 17
Inari Medical, Inc. to Report Q2, 2024 Results on Jul 30, 2024 Jul 17
Now 22% overvalued after recent price rise Jul 12
Inari Medical: A Touch Of Uncertainty And Overvaluation Jul 05
CEO, President & Director notifies of intention to sell stock Jul 04
Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inari Medical, Inc Jun 22
At US$43.23, Is It Time To Put Inari Medical, Inc. (NASDAQ:NARI) On Your Watch List? Jun 18
Chief Financial Officer notifies of intention to sell stock Jun 14
Director notifies of intention to sell stock May 30
Now 22% overvalued May 24
Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher May 23
Chief Financial Officer exercised options and sold US$273k worth of stock May 17 Grant & Eisenhofer Files Class Action Lawsuit Against Inari Medical, Inc., William Hoffman, Andrew Hykes, and Mitch C. Hill on Behalf of Institutional Investor May 14
Consensus EPS estimates fall by 73%, revenue upgraded May 07
Inari Medical, Inc. Provides Earnings Guidance for the Full Year 2024 May 03
Price target decreased by 7.4% to US$66.00 May 02
Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount? May 02
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 01
Inari Medical, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 19
Chief Financial Officer exercised options and sold US$243k worth of stock Apr 17
Inari Medical, Inc. Appoints Tim Benner as Senior Vice President of U.S. Sales Apr 03
Inari Medical: Buy On Growing TAM Mar 27
Chief Financial Officer notifies of intention to sell stock Mar 15
Inari Medical, Inc., Annual General Meeting, Apr 24, 2024 Mar 14
Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry Mar 13
Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge Mar 08
Consensus EPS estimates fall by 325% Mar 07
Price target decreased by 7.5% to US$76.50 Feb 29
Full year 2023 earnings: EPS misses analyst expectations Feb 29
Inari Medical, Inc. Provides Revenue Guidance for the Full Year 2024 Feb 29
Inari Medical, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Consensus EPS estimates fall by 16% Jan 10
Inari Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year of 2023 and 2024 Jan 09
Chief Financial Officer exercised options and sold US$405k worth of stock Dec 17
Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)? Dec 14
Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study Nov 29
Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study Nov 28
CEO, President & Director recently sold US$2.2m worth of stock Nov 19
Inari Medical, Inc. (NasdaqGS:NARI) completed the acquisition of LimFlow SA. Nov 17
CEO, President & Director notifies of intention to sell stock Nov 16
Independent Chair of the Board recently bought US$3.0m worth of stock Nov 10 Inari Medical, Inc. (NasdaqGS:NARI) agreed to acquire LimFlow SA for $415 million.
New minor risk - Share price stability Nov 03
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 02
A Look At The Fair Value Of Inari Medical, Inc. (NASDAQ:NARI) Oct 23
Chief Financial Officer notifies of intention to sell stock Oct 15
Inari Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 12
Inari Medical (NASDAQ:NARI) Is In A Strong Position To Grow Its Business Sep 18
Chief Financial Officer exercised options and sold US$438k worth of stock Sep 17
CEO, President & Director recently sold US$2.4m worth of stock Aug 21
CEO, President & Director notifies of intention to sell stock Aug 17
Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued? Aug 14
Inari Medical, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate Jul 25
Chief Financial Officer exercised options and sold US$363k worth of stock Jul 16
Inari Medical, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 14
We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth Jun 18
Chief Financial Officer notifies of intention to sell stock Jun 16
Inari Medical, Inc. Announces Commercial Launch of Revcore and Triever16 Curve, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism Jun 08
Inari Medical, Inc Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients May 23
Director recently sold US$5.7m worth of stock May 21
Director notifies of intention to sell stock May 18
Consensus estimates of losses per share improve by 58% May 10
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 05
Inari Medical, Inc. Revises Revenue Guidance for the Full Year 2023 May 04
Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues Apr 17
Chief Financial Officer exercised options and sold US$415k worth of stock Apr 17
Independent Director exercised options and sold US$1.6m worth of stock Mar 19
Chief Medical Officer exercised options and sold US$563k worth of stock Mar 06
Full year 2022 earnings: EPS exceeds analyst expectations Mar 01
Consensus EPS estimates fall by 78%, revenue upgraded Mar 01
Chief Financial Officer notifies of intention to sell stock Feb 17
Inari Medical, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 08 Shareholder Returns NARI US Medical Equipment US Market 7D -0.3% -1.5% -2.4% 1Y -15.6% 10.0% 23.4%
See full shareholder returns
Return vs Market: NARI underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is NARI's price volatile compared to industry and market? NARI volatility NARI Average Weekly Movement 7.1% Medical Equipment Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: NARI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NARI's weekly volatility (7%) has been stable over the past year.
About the Company Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons.
Show more Inari Medical, Inc. Fundamentals Summary How do Inari Medical's earnings and revenue compare to its market cap? NARI fundamental statistics Market cap US$3.25b Earnings (TTM ) -US$78.58m Revenue (TTM ) US$574.50m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NARI income statement (TTM ) Revenue US$574.50m Cost of Revenue US$75.74m Gross Profit US$498.76m Other Expenses US$577.34m Earnings -US$78.58m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.34 Gross Margin 86.82% Net Profit Margin -13.68% Debt/Equity Ratio 0%
How did NARI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 02:20 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Inari Medical, Inc. is covered by 20 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Rescott Baird null null Baird Nisala Weerasuriya Berenberg
Show 17 more analysts 
